Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
481-500 of 847 trials

Ovarian Cancer: Olaparib and Durvalumab Study

We are exploring whether Olaparib alone or with Durvalumab can be safely given to patients with high-grade ovarian cancer before surgery. This study may help us learn more about treatment effectiveness and safety.

Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Danicopan for Pediatric PNH Patients

We are studying whether adding danicopan to existing treatments helps children with Paroxysmal Nocturnal Hemoglobinuria improve their hemoglobin levels and quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyPediatrics

Duchenne Muscular Dystrophy: Givinostat Study for Young Boys

We are studying the safety and effects of givinostat in boys aged 2 to under 6 years with Duchenne Muscular Dystrophy. This trial aims to understand how the drug works in their bodies and its impact on muscle function.

Duchenne Muscular DystrophyEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOrthopedics and Traumatology

Prurigo Nodularis: Povorcitinib Treatment Study

We are studying the effects of povorcitinib on itching and skin lesions in people with prurigo nodularis. The goal is to see if it improves symptoms and quality of life while ensuring safety.

Prurigo Nodularis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Recurrent Solid Tumors: OBT076 Treatment Study

We are testing the safety and effectiveness of OBT076 in patients with recurrent or metastatic CD205-positive solid tumors. This study will also explore how it works with another treatment called balstilimab.

Malignant Solid Tumor1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Acromegaly: Paltusotine Treatment Study

We are studying the long-term safety and effectiveness of paltusotine for people with acromegaly. This research aims to improve treatment options for managing this condition.

Acromegaly>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinology

Carcinoid Syndrome: Paltusotine Treatment Study

We are evaluating the safety and how the body processes different doses of paltusotine in people with carcinoid syndrome. This study aims to ensure the treatment is safe and well-tolerated.

Carcinoid Syndrome3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Painful Venous Malformations: Apixaban Study

We are investigating whether apixaban can help reduce pain and improve quality of life for patients with painful venous malformations. The study also looks at safety and how the medication affects blood clotting.

Venous Malformation1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyInternal Medicine

Diffuse Cutaneous Systemic Sclerosis: Ianalumab Study

We are testing a new medication, ianalumab, for people with diffuse cutaneous systemic sclerosis. The goal is to see if it improves symptoms and lung function compared to a placebo.

Systemic Scleroderma>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Pasireotide for Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

We are studying whether pasireotide can help patients with specific cancers live longer without their disease progressing. This trial focuses on those with synovial sarcoma and desmoplastic small round cell tumor.

Locally Advanced or Metastatic Synovial SarcomaLocally Advanced or Metastatic Desmoplastic Small Round Cell Tumor>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Knee Osteoarthritis: Intra-Articular Clodronate Study

We are investigating whether different doses of clodronate can help reduce knee pain and improve function in people with painful knee osteoarthritis. The study will also monitor safety and tolerability of the treatment.

Knee Osteoarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Mantle Cell Lymphoma: Pirtobrutinib and Rituximab Study

We are evaluating a new treatment combining pirtobrutinib and rituximab for patients with indolent Mantle Cell Lymphoma. The study aims to determine its effectiveness and safety compared to standard therapies.

Mantle Cell Lymphoma1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inhaled Molgramostim for Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

We are studying the effects of inhaled molgramostim in children and teens with aPAP. The goal is to see if it is safe and effective for improving their condition.

Pulmonary Alveolar Proteinosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsPulmonology

Haemophilia A: Efanesoctocog Alfa Treatment Study

We are investigating how efanesoctocog alfa affects joint health in patients with haemophilia A. The study aims to understand improvements in joint swelling and overall health during treatment.

Haemophilia A1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOrthopedics and Traumatology

Colorectal Cancer: Encorafenib and Cetuximab with Pembrolizumab

We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Generalized Myasthenia Gravis: Telitacicept Study

We are testing a new treatment called telitacicept for people with generalized myasthenia gravis. The study aims to see if it works better than a placebo and to check its safety.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurologyRheumatology

Pancreatic Cancer: Digitoxin and Chemotherapy Study

We are exploring whether adding digitoxin to chemotherapy can help improve survival for patients with inoperable pancreatic cancer. The trial also looks at treatment safety and quality of life.

Pancreatic Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

GLM101 for PMM2-CDG: Safety and Effects

We are studying the safety of GLM101 in patients with PMM2-CDG who have previously received the treatment. We will also look at its impact on coordination, balance, and sugar levels.

PMM2-CDGEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal Medicine